Crystalline Solid and Amorphous Forms of (-)-Halofenate and Methods Related Thereto
    1.
    发明申请
    Crystalline Solid and Amorphous Forms of (-)-Halofenate and Methods Related Thereto 有权
    ( - ) - 卤化物的结晶固体和无定形形式及其相关方法

    公开(公告)号:US20120232303A1

    公开(公告)日:2012-09-13

    申请号:US13470142

    申请日:2012-05-11

    IPC分类号: C07C233/18

    摘要: The present invention provides crystalline solid and amorphous forms of (−)-halofenate. The crystalline solid forms may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of conditions associated with blood lipid deposition in a mammal, particularly those diseases related to Type 2 diabetes and hyperlipidemia. The invention also relates to a method for preventing or treating Type 2 diabetes and hyperlipidemia in a mammal comprising the step of administering a therapeutically effective amount of crystalline solid and amorphous forms of (−)-halofenate.

    摘要翻译: 本发明提供( - ) - 卤代苯甲酸酯的结晶固体和无定形形式。 结晶固体形式可以用于各种药物组合物中,并且对于预防和/或治疗与哺乳动物血脂沉积相关的病症,特别是涉及2型糖尿病和高脂血症的疾病特别有效。 本发明还涉及一种用于预防或治疗哺乳动物的2型糖尿病和高脂血症的方法,其包括施用治疗有效量的( - ) - 氟酸盐的结晶固体和无定形形式的步骤。

    Crystalline solid and amorphous forms of (−)- halofenate and methods related thereto
    2.
    发明授权
    Crystalline solid and amorphous forms of (−)- halofenate and methods related thereto 有权
    ( - ) - 卤化物的结晶固体和无定形形式及其相关方法

    公开(公告)号:US08203019B2

    公开(公告)日:2012-06-19

    申请号:US11408609

    申请日:2006-04-20

    摘要: The present invention provides crystalline solid and amorphous forms of (−)-halofenate. The crystalline solid forms may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of conditions associated with blood lipid deposition in a mammal, particularly those diseases related to Type 2 diabetes and hyperlipidemia. The invention also relates to a method for preventing or treating Type 2 diabetes and hyperlipidemia in a mammal comprising the step of administering a therapeutically effective amount of crystalline solid and amorphous forms of (−)-halofenate.

    摘要翻译: 本发明提供( - ) - 卤代苯甲酸酯的结晶固体和无定形形式。 结晶固体形式可以用于各种药物组合物中,并且对于预防和/或治疗与哺乳动物血脂沉积相关的病症,特别是涉及2型糖尿病和高脂血症的疾病特别有效。 本发明还涉及一种用于预防或治疗哺乳动物的2型糖尿病和高脂血症的方法,其包括施用治疗有效量的( - ) - 氟酸盐的结晶固体和无定形形式的步骤。

    Crystalline solid and amorphous forms of (−)-halofenate and methods related thereto
    3.
    发明授权
    Crystalline solid and amorphous forms of (−)-halofenate and methods related thereto 有权
    ( - ) - 卤化物的结晶固体和无定形形式及其相关方法

    公开(公告)号:US08507719B2

    公开(公告)日:2013-08-13

    申请号:US13470142

    申请日:2012-05-11

    IPC分类号: C07C67/02

    摘要: The present invention provides crystalline solid and amorphous forms of (−)-halofenate. The crystalline solid forms may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of conditions associated with blood lipid deposition in a mammal, particularly those diseases related to Type 2 diabetes and hyperlipidemia. The invention also relates to a method for preventing or treating Type 2 diabetes and hyperlipidemia in a mammal comprising the step of administering a therapeutically effective amount of crystalline solid and amorphous forms of (−)-halofenate.

    摘要翻译: 本发明提供( - ) - 卤代苯甲酸酯的结晶固体和无定形形式。 结晶固体形式可以用于各种药物组合物中,并且对于预防和/或治疗与哺乳动物血脂沉积相关的病症,特别是涉及2型糖尿病和高脂血症的疾病特别有效。 本发明还涉及一种用于预防或治疗哺乳动物的2型糖尿病和高脂血症的方法,其包括施用治疗有效量的( - ) - 氟酸盐的结晶固体和无定形形式的步骤。

    Crystalline solid and amorphous forms of (-)- halofenate and methods related thereto
    4.
    发明申请
    Crystalline solid and amorphous forms of (-)- halofenate and methods related thereto 有权
    ( - ) - 卤化物的结晶固体和无定形形式及其相关方法

    公开(公告)号:US20080221018A1

    公开(公告)日:2008-09-11

    申请号:US11408609

    申请日:2006-04-20

    摘要: The present invention provides crystalline solid and amorphous forms of (−)-halofenate. The crystalline solid forms may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of conditions associated with blood lipid deposition in a mammal, particularly those diseases related to Type 2 diabetes and hyperlipidemia. The invention also relates to a method for preventing or treating Type 2 diabetes and hyperlipidemia in a mammal comprising the step of administering a therapeutically effective amount of crystalline solid and amorphous forms of (−)-halofenate.

    摘要翻译: 本发明提供( - ) - 卤代苯甲酸酯的结晶固体和无定形形式。 结晶固体形式可以用于各种药物组合物中,并且对于预防和/或治疗与哺乳动物血脂沉积相关的病症,特别是涉及2型糖尿病和高脂血症的疾病特别有效。 本发明还涉及一种用于预防或治疗哺乳动物的2型糖尿病和高脂血症的方法,其包括施用治疗有效量的( - ) - 氟酸盐的结晶固体和无定形形式的步骤。

    Hydrocodone polymorphs
    5.
    发明授权
    Hydrocodone polymorphs 有权
    氢可酮多晶型物

    公开(公告)号:US07625918B2

    公开(公告)日:2009-12-01

    申请号:US11371377

    申请日:2006-03-08

    IPC分类号: A61K31/485 C07D489/02

    CPC分类号: C07D489/02

    摘要: Hydrocodone bitartrate forms are disclosed which are useful as analgesic agents either in combination with or as replacements for hydrocodone bitartrate.

    摘要翻译: 公开了氢可酮酮酒石酸盐形式,其可用作止痛剂或与氢可酮酮酒石酸盐的组合或替代。

    Polymorphs of azabicyclohexane
    6.
    发明授权
    Polymorphs of azabicyclohexane 有权
    氮杂双环己烷的多晶型物

    公开(公告)号:US08765801B2

    公开(公告)日:2014-07-01

    申请号:US13366209

    申请日:2012-02-03

    摘要: The invention provides polymorphic crystalline forms of acid addition salts of (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane designated as polymorph form A, polymorph form B and polymorph form C, where polymorph form A is more thermodynamically stable than the other forms, methods for preparing and using such polymorph forms and pharmaceutical compositions containing such polymorph forms.

    摘要翻译: 本发明提供称为多晶型A,多晶型B和多晶型C的(+) - 1-(3,4-二氯苯基)-3-氮杂双环[3.1.0]己烷的酸加成盐的多晶型,其中多晶型 形式A比其他形式更热力学稳定,制备和使用这种多晶型形式的方法和含有这种多晶型形式的药物组合物。

    Novel Polymorphs Of Azabicyclohexane
    7.
    发明申请
    Novel Polymorphs Of Azabicyclohexane 审中-公开
    氮杂双环己烷的新型多晶型物

    公开(公告)号:US20110294847A1

    公开(公告)日:2011-12-01

    申请号:US13207144

    申请日:2011-08-10

    摘要: The invention provides polymorphic crystalline forms of acid addition salts of (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane designated as polymorph form A, polymorph form B and polymorph form C, where polymorph form A is more thermodynamically stable than the other forms, methods for preparing and using such polymorph forms and pharmaceutical compositions containing such polymorph forms.

    摘要翻译: 本发明提供称为多晶型A,多晶型B和多晶型C的(+) - 1-(3,4-二氯苯基)-3-氮杂双环[3.1.0]己烷的酸加成盐的多晶型,其中多晶型 形式A比其他形式更热力学稳定,制备和使用这种多晶型形式的方法和含有这种多晶型形式的药物组合物。